Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Not Confirmed
Not Confirmed
03-06 May, 2026
Bioequity EuropeBioequity Europe
Not Confirmed
Not Confirmed
04-06 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Arvo
Not Confirmed
Contact SupplierArvo
Industry Trade Show
Not Confirmed
03-07 May, 2026
AOCS Annual MeetingAOCS Annual Meeting
Industry Trade Show
Not Confirmed
03-06 May, 2026
Bioequity EuropeBioequity Europe
Industry Trade Show
Not Confirmed
04-06 May, 2026
Digital content
NEWS #PharmaBuzz
09 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/09/3202077/0/en/Actimed-Therapeutics-to-Highlight-Advancing-Clinical-Pipeline-with-New-Data-Presentations-at-18th-Annual-Conference-on-Sarcopenia-Cachexia-and-Wasting-Disorders.html
22 Nov 2025
// PRESS RELEASE
https://www.mankindpharma.com/media/press-release/actimed-therapeutics-announces-important-licensing-agreement-with-mankind-pharma/
25 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/25/3104816/0/en/Actimed-Therapeutics-Enrolls-First-Patients-in-Phase-2a-PROACT-Study-Programme-to-Assess-S-pindolol-benzoate-in-Obese-Patients-During-and-Post-GLP-1-Agonist-Therapy.html
20 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/20/3084550/0/en/Actimed-Therapeutics-Announces-New-Programme-to-Investigate-Potential-Muscle-Preservation-Effects-of-S-pindolol-Benzoate-in-Obese-Patients-Treated-with-GLP-1-Agonists.html
24 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/24/3067112/0/en/Actimed-Therapeutics-Appoints-Shaun-Claydon-as-Chief-Financial-Officer.html
06 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/06/3021736/0/en/Actimed-Therapeutics-Expands-Intellectual-Property-Portfolio.html
Drugs in Development
Details:
Through the licensing deal for S-pindolol Benzoate, the agreement aims to address cachexia by targeting 5-HT1A, beta-1, and beta-2 receptors.
Lead Product(s): Pindolol benzoate, (S)-
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Mankind Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 20, 2025
Lead Product(s) : Pindolol benzoate, (S)-
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Mankind Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mankind Pharma Signs Pact with Actimed for Cachexia Treatment
Details : Through the licensing deal for S-pindolol Benzoate, the agreement aims to address cachexia by targeting 5-HT1A, beta-1, and beta-2 receptors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 20, 2025
Details:
(S)-Pindolol Benzoate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Lead Product(s): Pindolol benzoate, (S)-,Semaglutide
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: SCIRENT Clinical Research and Science d.o.o.
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 03, 2025
Lead Product(s) : Pindolol benzoate, (S)-,Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : SCIRENT Clinical Research and Science d.o.o.
Deal Size : Inapplicable
Deal Type : Inapplicable
ACM-001.1 Effect On Lean Body Mass In Obese Patients During/Post Semaglutide Therapy
Details : (S)-Pindolol Benzoate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2025
Details:
Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an ACTA targeting multiple pathways that drive cancer cachexia.
Lead Product(s): S-Pindolol Benzoate
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 20, 2025
Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Actimed to Study S-pindolol’s Muscle-Preserving Effects in Obese GLP-1 Patients
Details : Actimed is currently preparing for further clinical studies of its lead product ACM-001.1 (S-pindolol benzoate) which is an ACTA targeting multiple pathways that drive cancer cachexia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 20, 2025
Details:
ACM-002 (S-oxprenolol) has demonstrated slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection in amyotrophic lateral sclerosis (ALS).
Lead Product(s): Oxprenolol
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2024
Lead Product(s) : Oxprenolol
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Actimed Therapeutics Granted FDA Orphan Drug Status for ALS Treatment ACM-002
Details : ACM-002 (S-oxprenolol) has demonstrated slowing disease progression, improvement in survival, attenuation of muscle loss, motor neuron protection in amyotrophic lateral sclerosis (ALS).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2024
Details:
ACM-001.1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cachexia.
Lead Product(s): Pindolol benzoate, (S)-,Pindolol
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Quotient Sciences
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 08, 2023
Lead Product(s) : Pindolol benzoate, (S)-,Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACM-001.1 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cachexia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2023
Details:
ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2/3 clinical data in cachexia associated with colorectal cancer (IMPACT CRC) and another in patients with non-small cell lung cancer.
Lead Product(s): S-Pindolol Benzoate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 07, 2023
Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2/3 clinical data in cachexia associated with colorectal cancer (IMPACT CRC) and another in patients with non-small cell lung...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 07, 2023
Details:
The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.
Lead Product(s): S-Pindolol Benzoate
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Mankind Pharma
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 26, 2023
Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Mankind Pharma
Deal Size : $6.3 million
Deal Type : Series A Financing
Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of £5 Million to Advance Cli...
Details : The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorect...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 26, 2023
Details:
ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Lead Product(s): Pindolol
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Mankind Pharma
Deal Size: $12.1 million Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2023
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Mankind Pharma
Deal Size : $12.1 million
Deal Type : Financing
Actimed Therapeutics Successfully Closes Second Tranche Of £10m Seed Financing To Progress Pipeli...
Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 04, 2023
Details:
S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Lead Product(s): Pindolol
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 13, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 13, 2021
Details:
The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Lead Product(s): Pindolol
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 10, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $3.4 million
Deal Type : Series B Financing
Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round
Details : The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
